Trial reportThe journal of allergy and clinical immunology. In practice
A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder.
Trial report in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis.The British journal of psychiatry : the journal of mental science · 2025Pooled it
- Impact of interventions targeting anxiety and depression in adults with asthma.The Journal of asthma : official journal of the Association for the Care of Asthma · 2022Trial
- Article
- Modelling Asthma Treatment Dynamics: Insights from the g-Formula.Clinical epidemiology · 2025Article
- Risk Factors for Acute Asthma Exacerbations in Adults With Mild Asthma.The journal of allergy and clinical immunology. In practice · 2024Article
- Systemic Inflammation in Asthma: What Are the Risks and Impacts Outside the Airway?The journal of allergy and clinical immunology. In practice · 2024Review
- Management of the pediatric patient with asthma and obesity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024Review
- 5-HTP inhibits eosinophilia via intracellular endothelial 5-HTRs; SNPs in 5-HTRs associate with asthmatic lung function.Frontiers in allergy · 2024Article
- Research Trends and Hotspots on Asthma and Depression: A Bibliometric Analysis.Journal of asthma and allergy · 2024Review
- Inhibitory effects of fluoxetine on the secretion of inflammatory mediators and JAK/STAT3 and JNK/TLR4 gene expression.Molecular biology reports · 2023Article
- Article
- Review
- The Detrimental Clinical Associations of Anxiety and Depression with Difficult Asthma Outcomes.Journal of personalized medicine · 2022Article
- The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children.The journal of allergy and clinical immunology. In practice · 2022Article
- Role of amygdala in stress-induced upregulation of airway IL-1 signaling in asthma.Biological psychology · 2022Article
- Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19.Frontiers in pharmacology · 2022Review
- Vascular Endothelial Growth Factor as a Putative Biomarker of Depression in Asthmatics with Reversible Airway Narrowing.Journal of clinical medicine · 2021Article
- Nonrespiratory Comorbidities in Asthma.The journal of allergy and clinical immunology. In practice · 2021Review
- Cumulative evidence for association of rhinitis and depression.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Review
- SSRIs: Applications in inflammatory lung disease and implications for COVID-19.Neuropsychopharmacology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDepression is common in asthma and is associated with poor outcomes. However, antidepressant therapy in depressed patients with asthma has been the topic of little research.
objectiveThis study examined the impact of antidepressant treatment with escitalopram versus placebo on the Hamilton Rating Scale for Depression (HRSD), Inventory of Depressive Symptomatology-Self Report (IDS-SR), Asthma Control Questionnaire (ACQ), and oral corticosteroid use in patients with asthma and major depressive disorder (MDD).
methodsSingle-site 12-week, randomized, double-blind, placebo-controlled, parallel-group trial of escitalopram (10 mg/d) was conducted in 139 outpatients with asthma and MDD. Randomization was stratified by oral corticosteroid use (≥3 bursts in past 12 months, yes or no) and baseline depressive symptom severity (HRSD score ≥ 20) (higher severity, n = 42) versus less than 3 bursts, HRSD score less than 20, or both (lower severity, n = 97). The primary data analysis was conducted using hierarchical linear modeling Version 7.01 on the higher and lower severity samples and post hoc was conducted on the combined sample.
resultsAmong the higher severity completers (n = 21), a significant reduction in the ACQ score (P = .04) and oral corticosteroid use (P = .04) was observed with escitalopram. In the combined sample, no significant differences were observed, but a trend toward greater reduction in the IDS-SR score was observed with escitalopram (P = .07). Side effects were comparable across groups.
conclusionsThe findings suggest that patients with more severe asthma and depression symptomatology may have a positive response, in terms of both asthma and depressive symptom reduction, to antidepressant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.